课题基金 / 基金详情

Myocardial Ischemia and Transfusion (MINT) - DCC

Myocardial Ischemia and Transfusion (MINT) - DCC
心肌缺血和输血 (MINT) - DCC
批准号:
10290738
负责人:
Maria Mori Brooks
金额:
$75.05万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-01 至 2024-08-31
关键词:
AcuteAcute myocardial infarctionAddressAdoptionAdverse eventAnemiaAutomobile DrivingBlood TransfusionCanadaCardiovascular systemCarrying CapacitiesCessation of lifeClassificationClinicalClinical InvestigatorClinical TrialsClinical Trials Data Monitoring CommitteesCommunitiesCongestive Heart FailureCoronary heart diseaseDataData AnalysesData CollectionData Coordinating CenterData ReportingData SetDatabasesDropsElectrocardiogramEnsureEventExclusion CriteriaGuidelinesHemoglobinHemoglobin concentration resultHospitalsHuman ResourcesImmunityIncidenceInfrastructureIntentionInterventionLeadershipLength of StayManualsManuscriptsMeasuresMediator of activation proteinMedicalMethodsMonitorMyocardial InfarctionMyocardial IschemiaNational Heart, Lung, and Blood InstituteOutcomeOxygenPatient-Focused OutcomesPatientsPilot ProjectsPneumoniaPositioning AttributePreparationProceduresProcessProtocols documentationQuality ControlQuality IndicatorQuality of CareRandomizedRandomized Clinical TrialsRecurrenceReportingRiskSchemeShapesSiteSpecific qualifier valueStatistical Data InterpretationSystemThromboembolismTrainingTransfusionTreatment EffectivenessUncertaintyUnited StatesUnited States National Institutes of HealthUniversitiesVariantWood materialWritingadverse outcomebaseclinical centerclinical practiceclinical research sitedata centersdata managementdata qualitydata resourcedesignepidemiologic dataexperiencehigh riskhospital readmissioninclusion criteriamedical schoolsmortalitymortality riskoperationpatient populationpilot trialpragmatic trialsystematic reviewthrombotictreatment strategyuser-friendly

项目摘要

项目成果

Maria Mori Brooks的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结
英文摘要
PROJECT SUMMARY Accumulating evidence from clinical trials suggests that a restrictive transfusion strategy is safe in most clinical settings. However, a low oxygen carrying capacity from moderate anemia may be deleterious in patients with cardiac ischemia. The potential for harm associated with anemia in patients with acute symptomatic coronary disease is supported by pathophysiological data that maintaining higher hemoglobin levels could benefit the ischemic heart by increasing oxygen delivery. Furthermore, results of the 110 patient MINT pilot trial found that all-cause mortality at 30 days was less frequent with a liberal transfusion strategy, 1 patient (1.8%), compared with a restrictive transfusion strategy, 7 patients (13.0%), (p=0.032). Systematic reviews of clinical trials evaluating transfusion strategies in patients with known ischemic heart disease document the absence of high quality data which has resulted in an ongoing controversy. The lack of high quality evidence to guide transfusions in patients with acute myocardial infarction has been cited in several major guidelines as well as by an NIH expert panel. Despite this, blood transfusions are being used as a negative indicator of quality of care by major organizations driving the adoption of restrictive strategies. The potential for adverse outcomes is real and immediate. In this multicenter pragmatic trial, we will activate 40 clinical centers and will randomly allocate 3500 patients at risk of myocardial ischemia with acute myocardial infarction and hemoglobin concentration less than 10 g/dL to be treated either according to a restrictive or liberal blood transfusion strategy. Our Primary Aim will be to determine whether a liberal transfusion threshold strategy (10 g/dL) is superior and will result in lower rates of either all cause mortality or acute myocardial infarction within 30 days following randomization as compared with a restrictive transfusion threshold strategy (8 g/dL). Our secondary aims will examine the effect of a liberal transfusion strategy compared with a restrictive transfusion strategy on adverse outcomes of transfusion related to volume overload, thrombotic risk and modified immunity. We will compare 30-day rates of congestive heart failure, thromboembolism, and pneumonia. We will also compare rates of 30-day death, cardiovascular death, myocardial infarction, and unscheduled revascularization, as well as hospital length of stay, and readmission to the hospital. We will contact the patients at 6 months to determine if the early effects on mortality are sustained or possibly enhanced. Relevance MINT is positioned to determine the threshold for blood transfusions in patients with acute myocardial infarction to minimize death and subsequent heart attacks. Given the high incidence of acute myocardial infarction, the results of MINT can shape clinical practice.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Core 3: Data Collection & Data Management Core
Core 1: Administrative Core
The Study of Women's Health Across the Nation (SWAN): The Impact of Midlife and the Menopause Transition on Health and Functioning in Early Old Age
Core 1: Administrative Core
海外基金